Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Jun 15;173(12):1348-55.
doi: 10.1164/rccm.200505-820OC. Epub 2006 Apr 7.

Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia

Mirelle Koeman  1 , Andre J A M van der Ven, Eelko Hak, Hans C A Joore, Karin Kaasjager, Annemarie G A de Smet, Graham Ramsay, Tom P J Dormans, Leon P H J Aarts, Ernst E de Bel, Willem N M Hustinx, Ingeborg van der Tweel, Andy M Hoepelman, Marc J M Bonten
Affiliations
Randomized Controlled Trial

Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia

Mirelle Koeman et al. Am J Respir Crit Care Med. .

Abstract

Rationale: Ventilator-associated pneumonia (VAP) is the most frequently occurring nosocomial infection associated with increased morbidity and mortality. Although oral decontamination with antibiotics reduces incidences of VAP, it is not recommended because of potential selection of antibiotic-resistant pathogens. We hypothesized that oral decontamination with either chlorhexidine (CHX, 2%) or CHX/colistin (CHX/COL, 2%/2%) would reduce and postpone development of VAP, and oral and endotracheal colonization.

Objectives: To determine the effect of oral decontamination with CHX or CHX/COL on VAP incidence and time to development of VAP.

Methods: Consecutive patients needing mechanical ventilation for 48 h or more were enrolled in a randomized, double-blind, placebo-controlled trial with three arms: CHX, CHX/COL, and placebo (PLAC). Trial medication was applied every 6 h into the buccal cavity. Oropharyngeal swabs were obtained daily and quantitatively analyzed for gram-positive and gram-negative microorganisms. Endotracheal colonization was monitored twice weekly.

Results: Of 385 patients included, 130 received PLAC, 127 CHX and 128 CHX/COL. Baseline characteristics were comparable. The daily risk of VAP was reduced in both treatment groups compared with PLAC: 65% (hazard ratio [HR]=0.352; 95% confidence interval [CI], 0.160, 0. 791; p=0.012) for CHX and 55% (HR=0.454; 95% CI, 0.224, 0. 925; p=0.030) for CHX/COL. CHX/COL provided significant reduction in oropharyngeal colonization with both gram-negative and gram-positive microorganisms, whereas CHX mostly affected gram-positive microorganisms. Endotracheal colonization was reduced for CHX/COL patients and to a lesser extent for CHX patients. No differences in duration of mechanical ventilation, intensive care unit stay, or intensive care unit survival could be demonstrated.

Conclusions: Topical oral decontamination with CHX or CHX/COL reduces the incidence of VAP.

PubMed Disclaimer

Comment in

Publication types

MeSH terms